Vise Technologies Inc. Has $4.67 Million Holdings in AbbVie Inc. (NYSE:ABBV)

Vise Technologies Inc. increased its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 28.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 26,275 shares of the company's stock after acquiring an additional 5,830 shares during the quarter. Vise Technologies Inc.'s holdings in AbbVie were worth $4,669,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Fiduciary Advisors Inc. purchased a new position in shares of AbbVie during the fourth quarter valued at $29,000. EnRich Financial Partners LLC grew its holdings in shares of AbbVie by 196.4% during the fourth quarter. EnRich Financial Partners LLC now owns 166 shares of the company's stock valued at $29,000 after buying an additional 110 shares in the last quarter. Promus Capital LLC purchased a new position in shares of AbbVie during the fourth quarter valued at $30,000. Bradley & Co. Private Wealth Management LLC purchased a new position in shares of AbbVie during the fourth quarter valued at $31,000. Finally, Prudent Man Investment Management Inc. purchased a new position in shares of AbbVie during the fourth quarter valued at $32,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Stock Performance

Shares of NYSE ABBV traded up $0.97 during trading hours on Friday, hitting $183.51. 4,026,933 shares of the company's stock were exchanged, compared to its average volume of 6,254,319. AbbVie Inc. has a 1-year low of $153.58 and a 1-year high of $218.66. The company has a debt-to-equity ratio of 17.94, a current ratio of 0.66 and a quick ratio of 0.55. The stock has a market capitalization of $324.15 billion, a price-to-earnings ratio of 76.46, a PEG ratio of 1.62 and a beta of 0.56. The company's 50-day moving average price is $188.39 and its 200-day moving average price is $186.43.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Friday, April 25th. The company reported $2.46 earnings per share for the quarter, topping the consensus estimate of $2.40 by $0.06. AbbVie had a return on equity of 296.28% and a net margin of 7.59%. The business had revenue of $13.34 billion during the quarter, compared to analysts' expectations of $12.91 billion. During the same quarter in the previous year, the firm earned $2.31 EPS. The firm's revenue was up 8.4% compared to the same quarter last year. On average, sell-side analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Cantor Fitzgerald started coverage on AbbVie in a report on Tuesday, April 22nd. They set an "overweight" rating and a $210.00 price target on the stock. The Goldman Sachs Group restated a "neutral" rating and issued a $194.00 target price on shares of AbbVie in a research note on Tuesday, April 8th. Bank of America boosted their target price on AbbVie from $200.00 to $223.00 and gave the company a "neutral" rating in a research note on Tuesday, March 4th. UBS Group boosted their target price on AbbVie from $181.00 to $190.00 and gave the company a "neutral" rating in a research note on Monday, February 3rd. Finally, Citigroup restated a "neutral" rating and issued a $205.00 target price (down previously from $210.00) on shares of AbbVie in a research note on Wednesday, May 14th. Eight investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $210.95.

Insider Buying and Selling at AbbVie

In other AbbVie news, EVP Timothy J. Richmond sold 29,917 shares of the company's stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $202.90, for a total value of $6,070,159.30. Following the completion of the transaction, the executive vice president now owns 44,284 shares of the company's stock, valued at $8,985,223.60. This represents a 40.32% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Jeffrey Ryan Stewart sold 58,832 shares of the company's stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $210.08, for a total value of $12,359,426.56. Following the completion of the transaction, the executive vice president now directly owns 53,234 shares of the company's stock, valued at approximately $11,183,398.72. This trade represents a 52.50% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 107,693 shares of company stock valued at $22,282,985 in the last quarter. Corporate insiders own 0.25% of the company's stock.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.